CA
NZ
UK
AU
IND
US
Oil prices remained volatile amid escalating tensions in the Middle East, particularly as the Iran war continues to escalate, deescalate, and then deescalate again. This uncertainty weighed heavily on US stocks, with the Dow Jones Industrial Average falling 0.75%, the S&P 500 sliding 0.36%, …
The AI boom has driven a significant surge in demand for high-bandwidth memory (HBM) semiconductors, benefiting AMD (NASDAQ:AMD) and other key players in the chip industry.
Amprius Technologies (NYSE: AMPX) has been initiated at Buy by Clear Street. This rating change may have a significant impact on the company's market valuation.
AlphaSense, a data platform used by institutional investors and financial analysts, has raised $350 million in funding at a valuation of $7.5 billion. This funding round sees the company surpass $600 million in ARR, a significant milestone in its growth trajectory.
Cohen & Company Inc. (NYSE: COHN) has announced a groundbreaking innovation in the use of biological engineering in highway right-of-way technology, aiming to revolutionize road safety and sustainability. This pioneering move is poised to redefine the infrastructure development landscape.
Shares in Bio-Rad Laboratories Inc. (NYSE: BIO) dipped 0.77% to USD 303.77 during trading today, despite the company's operational transformation and targeted innovation efforts driving growth amid global market headwinds. This follows a busy day of trading for the biotechnology sector.
Registered nurses at Baystate Franklin Medical Center, represented by the Massachusetts Nurses Association (MNA), will hold a banner action outside the Baystate Health &Amp; Wellness Center in Northampton on June 8, 2026, as they continue their fight for a fair union contract. This action …
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) has been upgraded to 'Outperform' from 'Sector Perform' by RBC Capital analysts. This notable change reflects the firm's renewed confidence in the company's prospects. This significant move demonstrates their revised stance on the firm's growth andRevenuetrajectory.
Arvinas, Inc. (NASDAQ: ARVN) secured the first PROTAC approval, marking a significant milestone for the company. This regulatory breakthrough underscores ARVN's commitment to pioneering degrader technology, a key area of focus in the pharmaceuticals sector.
This article is intended for informational purposes only and does not constituteInvestmentadvice or a recommendation to buy, sell, or hold any security. All information is sourced from publicly available data. Investors should conduct their ownDue Diligenceand consult a qualified financial adviser before making any …
Please wait processing your request...